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ABSTRACT 
Outcomes of Warfarin Therapy among Chinese Patients in Two 
Ambulatory Care Settings 
Background: Warfarin is the most commonly used oral-anticoagulant 
worldwide. The management of warfarin therapy is problematic because it is a 
drug with narrow therapeutic index and its effects are subjected to wide inter-
and intra-individual variability. Therefore, intense monitoring is often required to 
prevent the occurrence of bleeding or thromboembolism. Management of 
warfarin therapy in Chinese patients is even more challenging because Chinese 
patients are reported to be more sensitive to the anticoagulation effect of warfarin. 
In western countries, anticoagulation clinics were proven to improve the 
outcomes of patients on warfarin when compared to routine medical care and 
clinical pharmacist involvement in the anticoagulation clinics was also shown to 
have a positive impact on the outcomes of these patients. 
Objectives: To compare a clinical pharmacist-managed anticoagulation service 
with physician-managed anticoagulation service on clinical outcomes of warfarin 
therapy in an ambulatory care setting in Hong Kong, to determine the cost-
effectiveness of such a clinical pharmacist-managed anticoagulation clinic from 
the perspective of a public health organization and to compare patient 
satisfaction of these two services. 
Method: A two-year prospective randomized clinical trial was conducted at the 
anticoagulation clinic of a teaching hospital in Hong Kong. Patients aged 18 
years or older who required warfarin therapy for at least 3 months were recruited. 
Patients were randomised to the pharmacist-managed or physician-managed 
group. Primary clinical outcome was assessed by the percentage of patient-time 
spent within the target international normalized ratio (INR) range. The incidence 
of major thromboembolic events (TEs) and major bleeding were assessed as 
secondary clinical outcomes. The cost per patient per month (cPPPM) was 




Results: One hundred and forty-one patients were recruited at the 
anticoagulation clinic and 137 patients completed the study. Patients in 
pharmacist-managed group (n=68) were in target INR 64% of patient-time 
versus 59% in physician-managed group (n=69) (p<0.001). There was no 
significant difference in incidence of major TEs or bleeding. The cPPPM in 
pharmacist-managed group (USD76 土 95) (1USD=7.8HKD) was lower than that 
in physician-managed group (USD98 士 158) (p<0.001). The PSQ-18 score of 
pharmacist-managed group (3.8 ± 0.2) was higher than that of physician-
managed group (3.6 士 0.3) (p<0.001). 
Conclusion: The clinical pharmacist-managed anticoagulation service was more 
effective and less costly than the physician-managed service in achieving target 
INR control for Chinese patients on warfarin therapy. Patients were more 
satisfied with the anticoagulation service provided by the pharmacist than the 
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1.1 Anticoagulation effect of warfarin 
Warfarin is the most widely prescribed oral anticoagulant worldwide. In 
2003, there were 21.2 million prescriptions written for warfarin in the U S A alone. 
(Marketos M 2004) It is preferred over other oral anticoagulants such as 
acenocoumarol, anisindione and dicumarol because it has a more predictable 
response and causes fewer non-hemorrhagic complications. Warfarin is an 
indirectly acting anticoagulant which exerts its action through blocking the 
conversion of vitamin K from its epoxide to its reduced form (Figure 1). The 
reduced form of vitamin K is essential for the hepatic activation of the various 
clotting factors (II, VII, IX and X). As a consequence, clotting factors with 
reduced procoagulant activities are synthesized. (Ansell J et al 2004) 
glutamic acid (glu) y-carboxyglutamic acid (gla) 
> ^ < 
Vit K H
2
 (hydroquinone) Vit K O (epoxide) 
\ / 
K Reductase / KO Reductase 
Vit Ki (quinone) 
Warfarin blocks weakly Warfarin blocks strongly 
Figure 1. Effect of warfarin on the vitamin K cycle 
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1.2 Indications of warfarin therapy 
The number of patients receiving warfarin therapy is on the rise in the last 
decade. Warfarin has been proven to be efficacious in reducing the incidence of 
strokes in patients with non-valvular atrial fibrillation in several large clinical 
trials. (Petersen P et al 1989，SPAF Investigators 1991, E A F T Study Group 1993, 
Halperin, JL et al 1994, SPAF Investigator 1996) Pooled analysis of these clinical 
trials showed a 62-68% risk reduction of ischemic stroke annually in patients 
suffering from non-valvular atrial fibrillation. (Laupacis A et al 1998, Robert G H 
et al 1999) Besides, the clinical effectiveness of warfarin has already been well 
established in a number of indications. These include the prophylaxis and 
treatment of venous thrombosis and pulmonary embolism, and the prevention of 
ischemic stroke in patients with mechanical or tissue heart valve replacement. 
Moreover, warfarin is strongly recommended in certain patients with valvular 
heart diseases to reduce the risk of strokes, especially those with mitral valve 
problems, concomitant atrial fibrillation and a history of systemic embolism. In 
patients with myocardial infarction, warfarin is indicated to reduce the risk of 
death, recurrent myocardial infarction and thromboembolic events like stroke or 
systemic embolization. (Hirsh J et al 2001) 
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1.3 Monitoring systems for anticoagulation therapy 
In order to obtain optimum clinical response, an effective monitoring 
system is necessary so that patients on warfarin therapy can be monitored on a 
regular basis and kept at the desired level of anticoagulation at all times. In the 
past，prothrombin time (PT) was used to monitor oral anticoagulation therapy. The 
PT responds to a reduction of three vitamin K-dependent clotting factors (II, VII 
and X). The PT assay is performed by adding thromboplastin and calcium to 
citrated blood and the time until clot formation is measured in seconds. (Ansell et 
al 2004) The use of PT as a monitoring parameter was imprecise because different 
laboratories used thromboplastins with different responsiveness. Therefore, the PT 
values were not comparable between different laboratories and this was the major 
limitation causing different dosing of the oral anticoagulant in various settings. To 
solve this problem, the World Health Organization developed a reference standard, 
the international sensitivity index (ISI), to cater for the different responsiveness of 
the thromboplastin reagents and permit standardization. (ASHP Report 1995) This 
calibration model is the international normalized ratio (INR), calculated according 
to the following formula: 
ISI 
INR = (patient PT / mean normal PT) 
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1.4 Optimum target intensities for anticoagulation therapy 
Recommendations on the optimum target anticoagulation intensities of 
warfarin therapy for different indications have been published by the American 
College of Chest Physician (ACCP). In the latest 2004 A C C P Consensus 
Conference on Antithrombotic Therapy, it was recommended that a target 
intensity of INR 2.0 to 3.0 should be adopted for most of the indications (Table 1). 
Exceptions are those with certain types of mechanical prosthetic heart valves and 
after myocardial infarction, in which a higher target INR range is recommended. 
(Ansell et al 2004) 
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Table 1. Recommended therapeutic range for warfarin therapy 
Indications INR 
Prophylaxis of venous thrombosis (high-risk surgery)
a
 2.0-3.0 
Treatment of venous thrombosis 2.0-3.0 
Treatment of pulmonary embolism 2.0-3.0 
Prevention of systemic embolism 
-Tissue heart valves 2 0 3 0 
- A c u t e myocardial infarction 
- Valvular heart disease 
- Atrial fibrillation 
Mechanical prosthetic valves 2.5-3.5 
Bileaflet mechanical valve in aortic position 2.0-3.0 
a: High risk surgeries include: hip surgery, major gynecologic surgery and major 
orthopedic surgery. 
1.5 Factors affecting anticoagulation effect of warfarin 
Since warfarin has a narrow therapeutic index, the risk of hemorrhage and 
thromboembolism will be sharply increased if the intensity of anticoagulation is 
higher and lower than the target range, respectively. Moreover, the effect of 
warfarin is subjected to wide inter- and intra-individual variability. The variability 
in anticoagulation effect is multi-factorial and it is associated with age, weight, 
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dietary habits, race and genetics. (Kamali F et al 2004, Franco V et al 2004, Blann 
A et al 1999) Even for the same individual, dosage may need to be adjusted from 
time to time, due to a change in dietary habits, the use of other drugs and health 
supplements, and co-morbidities. (Kayser SR 2005) 
1.5.1 Drugs 
Numerous drugs are reported to interact with warfarin in the literature, 
although the mechanisms for the interactions cannot often be fully identified. 
Warfarin is a racemic mixture of two optically active isomers, the R-warfarin and 
the S-warfarin, with S-warfarin three to five times more potent than R-warfarin in 
terms of anticoagulation activity. Both isomers were metabolized by the 
cytochrome P450 (CYP) in the liver but each by a different pathway. The C Y P 
2C9 isoenzyme is mainly responsible for the metabolism of S-warfarin while the 
metabolism of R-warfarin is by multiple cytochromes including C Y P 1A2, CYP 
3A4 and carbonyl reductases. (Kaminsky LS et al 1997) Inhibition and induction 
of these isoenzymes (especially the 2C9 isoenzyme) can significantly augment or 
diminish the anticoagulation effect of warfarin. Drugs like co-trimoxazole, 
metronidazole and phenylbutazone inhibit the clearance of S-warfarin and 
potentiate the effect of warfarin. In contrast, drugs like cimetidine and omeprazole 
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which inhibit the metabolism of R-warfarin also enhance the effect of warfarin but 
only to a moderate degree. Amiodarone inhibits the clearance of both R- and 
S-warfarin and is reported to augment the effect of warfarin significantly. Besides, 
the effect of warfarin can be reduced by drugs like cholestyramine and sulcrafate 
as these drugs can bind warfarin in the gut, thereby preventing its absorption. 
(Hirsh J et al 2001, Holbrook A M et al 1996) 
1.5.2 Diet 
Since warfarin acts by interfering with the vitamin K cycle, increased or decreased 
intake of dietary vitamin K may influence the anticoagulation effect of warfarin. 
Food such as broccoli, kale, spinach and watercress that contain large amounts of 
vitamin K may decrease the effect of warfarin. It is best to advise the patients to 
maintain a stable diet but not to exclusively avoid vitamin K containing foods, in 
order to achieve a stable anticoagulation control. (Kayser SR 2005) 
1.5.3 Health supplements 
Health supplements including herbs, vitamins and minerals can potentially 
interact with warfarin, causing fatal hemorrhagic or thromboembolic sequelae. 
However, most of the information available in the literature is based on in vitro 
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data, animal studies or individual case reports and definitive cause-and-effect 
relationships have not been proven. Moreover, the mechanisms for the interactions 
cannot be identified in many of the cases. Supplements with documented reports 
to possibly increase the effect of warfarin include danshen, devil's claw, dong quai, 
papain and vitamin E. (Heck et al 2000) Those with documented reports to 
possibly decrease the effect of warfarin include coenzyme Q10, ginseng, green tea 
and St. John's wort. (Heck et al 2000, Awang D V C et al 2002) Herbs such as 
angelica root, feverfew, gingko, garlic, ginger, licorice root may increase the risk 
of bleeding and so should be used cautiously in patients on warfarin. (Heck et al 
2000, Awang D V C et al 2002) In fact, anticoagulated patients are generally 
advised not to self-treat with supplements because data are lacking on the safety 
of many of these supplements when co-administered with warfarin. 
1.5.4 Comorbidities 
Patients with certain comorbid conditions may have different warfarin dosages 
requirement due to alterations of warfarin sensitivity. Patients with uncontrolled 
congestive heart failure may have a 'relative' clotting factor deficiency and 
require a decrease in warfarin dose. Patients with liver diseases may have a 
reduced capacity to synthesize clotting factors and so require a lower warfarin 
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dose due to an increase in warfarin sensitivity. Patients who are nutritional 
deprived of vitamin K may also be more sensitive to the effect of warfarin and a 
reduced dose may be warranted. (Kayser SR 2005) Patients with thyroid 
dysfuncction may also need adjustment of warfarin dosage due to a change in the 
metabolism of the clotting factors. 
1.5.5 Genetic factors 
In recent years genetic variations have been found to be an important 
factor to influence the anticoagulation response to and the maintenance dose of 
warfarin therapy. As mentioned earlier, the C Y P 2C9 isoenzyme is largely 
responsible for the metabolism of the pharmacologically more potent S-warfarin. 
It was found that this isoenzyme did exhibit polymorphism The 2 most common 
variant alleles CYP2C9*2 and CYP2C9*3 cause a decreased enzymatic activity of 
30% and 80% respectively. (Higashi M K 2002) Patients with these allelic variants 
are less effective in metabolizing S-warfarin and require a lower maintenance 
dose than those with wild-type enzyme. Prevalence of this polymorphism is 
different in patients with different ethnic background. Approximately one third of 
the Caucasians carry one or more of these variant alleles but these are virtually 
non-existent in African-American, Japanese, Chinese and Korean population. 
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(Takahashi H et al 2003, Scordo M G et al, 2002, Aithal GP et al 1999, Lee C R et 
al 2002) 
Most recently, the gene which encodes the warfarin target protein, the 
vitamin K epoxide reductase complex 1 (VKORC1), has been identified. Rider et 
al identified 10 common single-nucleotide polymorphisms at the noncoding 
region of V K O R C 1 and inferred five major haplotypes. Two of the five 
haplotypes (HI and H2) are associated with a low-dose warfarin phenotype while 
the remaining three (H7, H8 and H9) with a high-dose warfarin phenotype. 
Moreover, they also found that the prevalence of these haplotypes was different 
among different races. In their study, Asian-American had a higher proportion of 
HI and H2 haplotypes (predictive of a low warfarin dose) and African-American a 
higher proportion of H7, H8 and H9 haplotypes (predictive of a high warfarin 
dose) when compared to the European-American. (Rieder et al 2005) 
1.6 Management of anticoagulation therapy in Chinese patients 
Management of warfarin therapy in Chinese patients poses an even greater 
challenge because Chinese patients are reported to be more sensitive to the 
anticoagulation effect of warfarin and require a lower maintenance dose when 
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compared to the Caucasians. (Weibert RT et al 1991, Yu et al 1996, Chenhsu R Y 
et al 2000) In a study conducted by Yu et al, the mean daily warfarin requirement 
for a target INR of 2-2.5 in 151 Chinese patients was 3.3mg 土 1.4mg. (Yu et al 
1996) In contrast, the mean maintenance dose for a target INR of 1.8-2.5 in 228 
Caucasian patients was nearly double at 6.1mg. (Routledge PA et al 1979) The 
difference in warfarin requirement cannot be simply explained by lower body 
weight in Chinese patients and different dietary habits. As mentioned above, 
genetic factors have been discovered to play an important role in the inter-racial 
difference of warfarin effect in recent years. Several studies have looked into the 
prevalence of these allelic variants in Asian population and it was found that the 
functionally defective CYP2C9*2 and *3 alleles appeared only in 0-2% of Asian 
population. (Lee C R et al 2002) Therefore, this mechanism still cannot explain 
why Chinese patients on warfarin therapy required a lower maintenance dose. 
Rieder et al reported that the frequency of V K O R C 1 HI and H2 
haplotypes (predictive of a low warfarin dose) was significantly higher in the 
Asian-American population than in the European-American population. (Rieder et 
al 2005) Another study conducted by Veenstra et al also found that the HI 
haplotype was the most common haplotype in a group of Hong Kong Chinese 
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patients on warfarin therapy and it was significantly associated with lower 
warfarin dosage. This genetic polymorphism in V K O R C 1 appears to be the key 
influential factor on the lower warfarin requirement among Chinese patients. 
(Veenstra et al 2005) 
1.7 Barriers to optimal INR control 
Considerable efforts are required to manage warfarin therapy well, both 
for the clinicians and patients. The clinicians need to monitor INR regularly in 
order to adjust warfarin doses accordingly. This is particularly imperative when 
patients are taking concomitant drugs or are having other co-morbidities. This 
makes the management of warfarin therapy labour intensive and costly. Moreover, 
since warfarin has a narrow therapeutic index, some physicians may still worry 
about the hemorrhagic complications even with frequent monitoring. 
From patients' perspective, taking warfarin may mean frequent follow-ups, 
frequent blood taking and strict dietary restrictions. With all these barriers, 
patients may refuse to take and physicians may be reluctant to prescribe warfarin 
even when it is clearly indicated. In order to improve this situation and the 
outcomes of patients, a more systematic way to manage warfarin with properly 
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trained medical personnel is warranted. 
1.8 Two models of care for anticoagulation therapy - routine 
medical care and coordinated anticoagulation service 
Since the 1980's, there have been a substantial number of studies 
evaluating the outcomes of warfarin therapy when patients were managed under 
coordinated anticoagulation management service (AMS) and routine medical care 
(RMC). The growing evidence suggested that A M S can achieve better outcomes 
when compared to (RMC). (Bussey H L et al 1996, Garabedian-Ruffalo S M et al 
1985, Cortelazzo S et al 1993，Wilt V M et al 1995, Wilson SJ et al 2003, Ellis RF 
et al 1992，Foss M T et al 1999) In fact, coordinated anticoagulation service has 
long been the standard of care in countries like the Netherlands and the United 
Kingdom, and it is the preferred model of care recommended by the ACCP. 
(Ansell et al 2004) 
1.9 Outcomes of two models of anticoagulation management 
1.9.1 Clinical Outcomes 
Several studies had looked into the adverse event rates when patients were 
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managed under R M C , but they were all retrospective in design. Nevertheless, a 
large number of patients with adequate patient-years of data were included in 
these studies to reflect the incidence of bleeding and thromboembolism when 
patients were managed in the model o f R M C . It was found that bleeding occurred 
in 5-8.1% per patient-year (Lanfield CS et al 1989, Beyth RJ et al 1998，Gitter MJ 
et al 1995) while thromboembolic rate was reported to be 8.1% per patient-year in 
one study (Gitter M J et al 1995). 
Similar issues were addressed in the setting of A M S from a number of 
studies. Again, these studies were all retrospective in nature and there were no 
control groups for comparison. Yet, several large studies provided a reflection on 
the efficacy and adverse event profiles of warfarin therapy when patients were 
managed in this type of setting. They found a major bleeding rate of 1.4-3.3% per 
patient-year (Van der Meer FJM et al 1993，Cannegieter SC et al 1995, Palareti G 
et al 1996 & 1997). Thromboembolism occurred in 0.7-3.5% per patient-year 
(Cannegieter SC et al 1995，Palareti G et al 1996 & 1997). From these figures, it 
seemed that the rates of bleeding and thromboembolism were generally lower 
when patients were managed in an A M S when compared to the R M C . 
A number of studies comparing the two models of management had been 
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conducted in the past two decades. Again, these studies were mostly retrospective 
in nature and patients were not randomized. Cortelazzo et al found that both the 
rates of major bleeding and thromboembolism were lower when patients were 
managed in an anticoagulation clinic (AC) when compared to the R M C . 
(Cortelazzo S et al 1993) Chiquette et al found that patients in the A C spent more 
time within the therapeutic range and had lower incidences of both 
warfarin-related hospital admissions and emergency department visits when 
compared to those managed by the R M C . (Chiquette E et al 1998) Chamberlain et 
al also reported similar findings that patients had lower frequencies of INRs 
extending outside the therapeutic range and a lower rate of hospital admission 
when they were managed in an A C instead of the R M C . (Chamberlain M A et al 
2001) The results of these trials, though each had its limitations, all suggested that 
the A M S could improve the clinical outcomes of patients on warfarin therapy 
when compared to the R M C . 
1.9.2 Economic Outcomes 
Coordinated care was also shown, in several overseas studies, to be cost 
saving when compared to the R M C (Chiquette E et al 1998, Wilt V M et al 1995). 
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They found that the lower incidences of warfarin-related bleeding and 
thromboembolism in patients managed by the ACs resulted in lower rates of 
hospital admissions and emergency department visits, leading to a significant 
decrease in the healthcare resources consumption. As a result, a substantial cost 
saving could be achieved when patients were managed in an anticoagulation 
clinic. 
1.10 Clinical pharmacist involvement in the management of 
anticoagulation therapy 
In western countries, the discipline of clinical pharmacy has been involved 
in the anticoagulation clinic for decades. Clinical pharmacists are well suited in 
this position because they are specialized in patient counseling and therapeutic 
drug monitoring. Moreover, with their drug expertise, they can promptly and 
readily identify warfarin-drug interactions and side effects of warfarin. The roles 
of clinical pharmacists in the anticoagulation clinic include providing therapeutic 
drug monitoring, warfarin dosage adjustment, triage of warfarin-related and 
unrelated problems, patient counseling and education, and the co-ordination of 
anticoagulation clinic activities. Various studies conducted in the western 
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populations have shown that clinical pharmacist-managed anticoagulation 
services decreased warfarin-related hospitalizations, lowered incidences of 
hemorrhagic and thromboembolic events, improved INR control and reduced the 
overall healthcare cost when compared to the routine medical care. (Wilt V M et al 
1995, Chiquette E et al 1998, Wilson SJ et al, 2003) However, there was no 
anticoagulation clinic managed by clinical pharmacist in Hong Kong before the 
implementation of this study. 
1.11 Anticoagulation management in Hong Kong 
In Hong Kong, most of the patients on warfarin therapy are managed by 
their primary care physicians with no particular algorithm used. In late 1990s, in 
view of the clinical benefits achieved with coordinated anticoagulation clinics in 
the western countries, a few anticoagulation clinics were started in various large 
public hospitals in Hong Kong. However, all these clinics were solely managed by 
physicians with no clinical involvement of pharmacists or nurses. 
You et al conducted a retrospective study to compare 2 cohorts of patients 
newly started on warfarin managed by a physician-managed A C and by the R M C 
in a public hospital in Hong Kong. They found that patients in the 
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physician-managed A C had a better INR control and lower incidences of 
warfarin-related complications when compared to those in the R M C . The total 
cost per patient-year was also found to be lower in the A C cohort. (You JHS et al, 
2003a) You et al constructed a Markov model to simulate over 10 years the 
outcomes of patients receiving warfarin therapy managed by a physician-managed 
A C or by R M C in Hong Kong. They estimated that the physician-managed A C 
could result in a cost saving as much as 40% due to a reduction in the number of 
warfarin-related hemorrhagic and thromboembolic events. (You JHS et al 2003b) 
These results showed that the benefits of ACs documented in western countries 
can potentially be extrapolated to the Hong Kong setting. 
1.12 Hypothesis and objectives 
As evidences suggest that a pharmacist-managed anticoagulation clinic 
can improve the treatment outcomes of patients on warfarin therapy, we proposed 
a new management model (with a pharmacist as the primary care provider) with 
the following hypothesis: 
A pharmacist-managed anticoagulation service (with back-up from physicians) is 
more effective than the current model (physician-managed anticoagulation clinic) 
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in achieving target INR control in Chinese patients receiving warfarin therapy in 
Hong Kong. 
The objectives of the present study were to: 
1. compare the effects of a clinical pharmacist-managed anticoagulation service 
with the physician-managed anticoagulation service on the clinical outcomes 
of warfarin therapy in an ambulatory care setting in Hong Kong; 
2. determine the cost-effectiveness of the clinical pharmacist-managed 
anticoagulation service for the management of warfarin patients from the 
perspective of a public health organization; 
3. compare patient satisfaction of the pharmacist-managed anticoagulation 
service with the physician-managed anticoagulation service. 
2 0 
Chapter Two 
Materials and Methods 
2 1 
2.1 Setting and subjects 
This was a two-year randomized clinical trial conducted from November 
2002 to September 2004 at the anticoagulation clinic of the Prince of Wales 
Hospital (PWH) in Hong Kong. P W H is a 1440-bed acute general hospital as well 
as the teaching hospital of the Faculty of Medicine, the Chinese University of 
Hong Kong. Specialty outpatient services are offered in the Li Ka Shing Specialist 
Clinic of P W H . As the number of patients indicated for long term warfarin was 
increased, it was decided to establish an anticoagulation clinic managed solely by 
physicians on a weekly basis in 1998. In 2002, this clinic managed approximately 
300 patients on warfarin therapy. 
Patients on warfarin therapy were referred to the anticoagulation clinic for 
follow up by their primary care physicians from other specialist clinics (e.g. 
cardiac clinic, diabetic clinic, obstetric clinic) or from wards after discharge. A 
clinical pharmacist-managed anticoagulation service was added to the clinic in 
2002. The present study was approved by the Joint Chinese University of Hong 
Kong-New Territories East Cluster Clinical Research Ethics Committee. 
Patients were recruited every week from the anticoagulation clinic from 
November 2002 to June 2004. One day before the anticoagulation clinic, the 
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clinical pharmacist screened the medical charts for all patients newly enrolled at 
the clinic for eligibility to enter the study. Patients were selected according to the 
following criteria: male or female Chinese patients aged 18 years of above with 
anticipated treatment duration of 3 months or more. W e excluded those patients 
who were pregnant and those with an anticipated duration of treatment less than 3 
months. 
At their first clinic visit, the clinical pharmacist explained to the new 
patients the details of the study. Those patients who agreed to participate and 
provided written consent were randomized to the physician-managed group (usual 
practice model) or the pharmacist-managed group (newly proposed model) 
according to a computer-generated table with random assignment in blocks of four. 
The patient were followed prospectively till September 2004 or until the patient 
was off warfarin (whichever occurred first). 
2.2 Interventions 
2.2.1 Newly proposed model 
2.2.1.1 Training of clinical pharmacist 
Patients in the pharmacist-managed group were managed by one clinical 
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pharmacist (Chan FWH). The clinical pharmacist received intensive training on 
warfarin management from the two haematologists (Cheng G, Wong R S M ) who 
managed the physician-managed clinic. Moreover, he was also arranged to attach 
at the physician-managed warfarin clinic for one month before the start of the 
pharmacist-managed clinic. 
2.2.1.2 Development of management protocol 
A management protocol was developed by a haematologist (Cheng G), a 
clinical pharmacologist (Chan TYK) and a pharmacotherapy specialist (You JHS) 
to guide the clinical pharmacist to manage patients on warfarin therapy. The 
management protocol included (appendix A): 
1. the target therapeutic INR ranges for various indications of warfarin therapy; 
2. a warfarin dosage adjustment protocol; 
3. conditions requiring physician consultation; 
4. lists of clinically significant warfarin-drug, warfarin-herb, warfarin-food and 
warfarin-disease interactions; 
5. criteria to determine follow-up intervals and additional follow-up visits and 
6. patient education materials for patients and caregivers 
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2.2.1.3 Treatment algorithm of the pharmacist-managed 
anticoagulation service 
Figure 2 showed the treatment algorithm of the pharmacist-managed 
service. A patient would be attended by a haematologist during the first clinic visit 
to decide on the duration of therapy and target INR range. In every subsequent 
follow-up visit, the patient would be attended by the clinical pharmacist. INR 
measurement would be obtained using a point-of-care testing monitor 
(CoaguChek Pro D M , Roche, Mannheim, Germany) at the clinic. The accuracy of 
CoaguChek Pro D M was validated with hospital laboratory as described later. The 
clinical pharmacist would screen for the criteria that required physician 
consultation, including INR over 4.5，INR failed to reach therapeutic range after 3 
visits, signs and symptoms of thromboembolism or major bleeding, patients who 
intended to undergo dental or other operations, and upon completion of intended 
treatment course to determine whether treatment should be continued. The clinical 
pharmacist paged the attending physician and he would guide the pharmacist 
either through the telephone or by coming directly to the clinic. 
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Figure 2. Treatment algorithm of the pharmacist-managed anticoagulation service 
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Those patients who received physician consultation would remain to be 
followed up in the pharmacist-managed clinic at the next clinic visit. For those 
patients who did not require physician consultation, the clinical pharmacist 
followed a predetermined management checklist to: 
1. check for signs of minor bleeding; 
2. identify potential warfarin-drug, warfarin-herb and warfarin-food 
interactions; 
3. monitor patient adherence by patient interview or pill counts and 
4. provide intense education to patients and caregivers on warfarin therapy. 
An intense patient education counselling included the indications and 
benefits of warfarin therapy, the symptoms of bleeding and thromboembolic 
events and their management, drugs, food supplement and herbs to avoid, missed 
dose management and precautions to take during warfarin therapy. Written patient 
information was also provided. 
Finally, the clinical pharmacist adjusted the warfarin dosage and scheduled 
the next follow-up visit according to the INR control. The patient would be 
followed every 2-6 weeks if a dosage adjustment was made and every 8-10 weeks 
if the same warfarin regimen continued. Between the clinic visits, the clinical 
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pharmacist conducted telephone follow-ups for those patients with questionable 
adherence (as assessed by patient interview and pill-counts) or difficult INR 
control. Pharmacist consultation of the warfarin therapy was available to the 
patients through a telephone hot-line in form of a paging service. 
2.2.1.4 Validation of the Coagucheck Pro DM 
The Coagucheck Pro D M was validated by using the method described by 
Havrda et al. (Havrda D E et al 2002) Since the laboratory INR values were the 
standard used for warfarin dosage adjustment in the hospital, the INR values 
obtained from the Coagucheck Pro D M were compared with the laboratory INR 
values. Around 20 patients were selected from the already established 
physician-managed clinic each week for the assessment for a total of four weeks. 
Each of these patients had a fingerstick to obtain the blood sample for the 
Coagucheck Pro D M and then a venous blood sample drawn within 15 minutes 
after the fingerstick to be sent to the hospital laboratory for INR determination. A 
total of 86 pairs of INR readings were included in the validation. The Coagucheck 
Pro D M INR values were significantly correlated to the laboratory INR values 
(r=0.92, p<0.01). Agreement for therapeutic decision with the Coagucheck Pro 
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D M was found 77% of the time. These findings were similar to other published 
reports which validated other similar point-of-care INR devices. (Gosselin R et al 
2000, Havrda D E et al 2002) 
2.2.2 Usual Practice Model 
The physician-run clinic was managed by the 2 haematologists (Cheng G, 
Wong RSM). N o support personnel such as nurses or physician trainees were used. 
INR measurements were performed by hospital laboratory testing. Patients 
therefore needed to have venous blood drawn two to three hours prior to their 
clinic appointment. During each consultation, the haematologists adjusted the 
warfarin dosage using the same dosage adjustment protocol as the 
pharmacist-managed group. The haematologists also monitored the signs and 
symptoms of thromboembolism and bleeding, drug interactions and patient's 
adherence, as their usual practice, and no pre-determined checklist was used. 
2.3 Outcome Measures 
2.3.1 Primary Clinical Outcome 
2.3.1.1 Therapeutic and expanded therapeutic INR ranges 
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The primary clinical outcome was the control oflNR per therapeutic range 
and per expanded therapeutic range. Therapeutic INR ranges for low intensity 
(INR = 2-3) and high intensity (INR = 2.5-3.5) indications were adopted from 
American College of Chest Physicians (ACCP) Consensus Conference on 
Antithrombotic Therapy. (Hirsch H et al 2001) Expanded therapeutic INR range, 
defined as the therapeutic range INR 士 0.2，was considered clinically acceptable 
and would not require dosage adjustment. (Anderson et al 2004) The INR value at 
each clinic visit was recorded for each study patient. The percentage of 
patient-time spent in the therapeutic (and expanded therapeutic) INR range was 
estimated using linear interpolation between measured INR values as described by 
Rosendaal et al. The control of INR was expressed as the distribution of 
patient-years spent among various INR ranges. 
2.3.1.2 A method to determine the amount of patient-time spent 
in each INR category 
Rosendaal et al developed a method to determine the amount of 
patient-time spent in each INR category. (Rosendaal FR et al, 1993) This method 
assumed that the INR value between two measurements varied linearly. The time 
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between the two measurements was divided in days and small steps of 0.1 INR 
over the range of the time interval was used. The INR was treated as gradually 
increasing or decreasing over the interval. For example, if a two week interval was 
bounded by an INR of 2.5 as the first and 3.1 as the second measurements, 2 days 
would be allocated to an INR of 2.5, 2 days to an INR of 2.6, 2 days to an INR of 
2.7 and so on. Subsequently, the person-time of these small steps was collapsed 
into larger cells of 0.5 INR (e.g . INR 2.0-2.4, 2.5-2.9) and then summed over all 
patients. 
2.3.2 Secondary Clinical Outcome 
The incidence of warfarin-related major complications per 100 
patient-years, as the secondary clinical outcome measurement, was also calculated 
for both study groups. Patients were interviewed at each follow-up visit to capture 
the incidences of warfarin-related major events which were defined as those 
events that required medical attendance or treatment, such as unscheduled 
outpatient clinic visits, emergency room visits and hospitalization. Major bleeding 
events included haemorrhagic stroke, gastrointestinal bleed, genitourinary bleed 
and hemoptysis. Major thromboembolic events included transient ischemic attack, 
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stroke, recurrent venous thrombosis and pulmonary embolism. Each event was 
confirmed by reviewing the patient's medical record (both computer and written 
records). 
2.3.3 Economic Outcome 
Direct healthcare cost for anticoagulation therapy including the cost for 
treatment of adverse drug events and major complications was assessed as the 
economic outcome measurement. The utilization of the following healthcare 
resources related to warfarin therapy were documented or retrieved from medical 
records to assess the total direct cost per patient: medications, laboratory and 
diagnostic tests, clinic visits, emergency room visit, and hospitalization. The total 
direct medical cost was presented as cost per patient per month (cPPPM). 
The unit cost of each target healthcare resource was estimated from the 
perspective of a public health organization in Hong Kong. The Hospital Authority 
is non-profit-making and the largest public health organization in Hong Kong. It 
charges patients who are non-residents of Hong Kong based upon the latest 
charges of healthcare services of public hospitals and clinics posted in the Hong 
Kong Gazette. Assuming the charges listed in the Gazette represent only the cost 
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components (including costs of labour and supplies) with no addition of profits, 
the costs associated with the target healthcare resources were therefore 
approximated using charges listed in the Hong Kong Gazette. Drug cost was 
based on Hospital Authority-specific acquisition cost. 
The pharmacist-managed service in the present study was operated as an 
experimental service and so no standard cost for clinic visit managed by 
pharmacists was available for reference. Since the salary of the clinical pharmacist 
was approximately 50% of the averaged salary of the 2 haematologists and salary 
of the health care professionals was the major component of the clinic cost, the 
cost of clinic visit in the pharmacist-managed group was therefore adjusted to be 
50% of the cost of a physician-managed specialist clinic visit. The cost of clinic 
visit included the labour cost of the clinical pharmacist for both the clinic 
management and phone call follow-ups, and the cost of physician time for 
occasional consultations. A sensitivity analysis was conducted to examine the 
effect of variation of the cost of clinic visit provided by pharmacist-managed 
group on the results of cost analysis. 
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2.3.4 Humanistic Outcome 
Patient satisfaction was determined by using the patient satisfaction 
questionnaire (PSQ)-18 (RAND Corporation, Santa Monica, CA, USA) which 
was completed after a patient had been recruited and followed for at least 3 
months. Each patient was interviewed using the PSQ-18 one time during the 
follow-up period. The questionnaire was administered by a research assistant who 
was not blinded to the patient allocation for both groups. Seven scales were 
assessed by PSQ-18: general satisfaction, technical quality, interpersonal manner, 
communication, financial aspects, time spent with clinician, and, accessibility and 
convenience. The overall mean score of the seven scales was also calculated in 
each study group. 
2.4 Sample size estimation 
It was estimated that the physician-managed anticoagulation service would 
achieve target INR about 50% of time, similar to routine medical care by 
physicians. Assuming that the pharmacist-managed anticoagulation service would 
increase the time of target INR control to 60% of time and the standard deviations 
of the means in the two groups were 0.25, a sample size of about 60 patients per 
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group would have a statistical power of 80% with an alpha error of 5 % to detect 
the difference. 
2.5 Statistical Analysis 
Statistical analysis was performed by Microsoft Excel 2000 (Microsoft 
Corporation, Redmond, W A , USA) and SPSS for Windows 11.5 (SPSS Inc., 
Chicago, IL, USA). Data were presented in mean 土 standard deviation (SD). 
Patient demographic, percentage of patient-time within therapeutic range of INR 
and incidence of bleeding and TEs between the two groups were compared by 
unpaired Student's t-test, Chi square test or Fisher's exact, where appropriate. A 
p-value of <0.05 was considered as statistically significant. 
The cPPPM of total direct medical resources consumed in either group 
was significantly skewed (p<0.001) and it could not be normalized by square-root, 
logarithm or arcsin transformation. It was therefore compared by Mann-Whitney 
test. The mean scores of the PSQ-18 subscales between the two groups were 





3.1 Patient demographics and indications 
From November 2002 to June 2004, 141 patients enrolled to the 
anticoagulation clinic were evaluated for eligibility of the study (Figure 3). Two 
patients had post-partum deep vein thrombosis and were initiated on warfarin for 
6 weeks and one patient refused to participate in the study. A total of 138 patients 
provided written consent and were randomized to the pharmacist-managed group 
(n=69) or the physician-managed group (n=69). One patient in the 
pharmacist-managed-group did not return for follow up after the first visit. The 
outcome analysis was conducted on the 68 patients in the pharmacist-managed 
group, and the 69 patients in the physician-managed group. A total of 62 
patient-years of data were available in the pharmacist-managed group and a total 
of 64 patient-years of data were available in the physician-managed group for the 
analysis. 
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Figure 3. Flow of the patients through the trial 
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The patients' demographic data were shown in Table 2. The mean age for 
the pharmacist-managed group was 58 土 14.0 years old and for the 
physician-managed group was 60 土 14.0 years old. Patients' characteristics in the 
two groups were similar with no significant difference in age and intensity of 
anticoagulation therapy. However, the pharmacist-managed group had a 
significantly fewer male patients when compared to the physician-managed group 
(35% versus 55%; p二0.031). Over 90% of patients in each group (63 patients in 
the pharmacist-managed group and 62 patients in the physician-managed group) 
were on warfarin therapy for a target INR 2-3. 
The indications for warfarin therapy in the study patients were shown in 
Table 3. The most common indication for warfarin therapy was atrial fibrillation 
(54% in the pharmacist-managed group and 51% in the physician-managed g r o u p ) , 
followed by heart valve replacement (15% in the pharmacist-managed group and 
20% in the physician-managed group), deep vein thrombosis (12% in the 
pharmacist-managed group and 13% in the physician-managed group) and 
pulmonary embolism (7% in the pharmacist-managed group and 6 % in the 
physician-managed group). There was no significant difference in the type of 
indications for warfarin therapy between the two groups. 
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Table 2. Patient demographics 
Number (%) P value 
Pharmacist-managed Physician-managed 
group group 
No. of Patients 68 69 -
Male 24 (35) 38 (55) 0.031 
Age (mean 士 SD) 58 ± 14.0 60 ± 14.0 0.484 
Patient-years 62 
Intensity of anticoagulation therapy 











The mean follow-up period for patients in the pharmacist group was 341 士 
190 days (range 13 -662 days) while that for patients in the physician group was 
334 土 202 days (range 12-675 days). In the pharmacist-managed clinic, 27 out 
of a total 481 pharmacist consultations (5.6%) required referral to the attending 
physician for further assessment. 
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Table 3. Indications for warfarin therapy 
Number (%) P value 
Pharmacist-managed Physician-managed 
group group 
Atrial fibrillation 37 (54) 35 (51) 0.794 
Heart valve replacement 





 0 , 7 2 5 







5 0 5 
Both mitral & aortic valve 1 (2) 4 (6) 0.371 
replacement 
Deep vein thrombosis 8(12) 9(1¾ 1.00 
Pulmonary embolism 5 (7) 4 (6) 0.745 
Cerebrovascular accident 2 (3) 2 (3) 1.00 















a: Arterial embolism (n=l) and ischemic heart disease (n=l) 
b: Ischemic heart disease (n=l) and arterial thrombosis (n二 1) 
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3.2 Control of INR 
The distributions of patient-years of the two study groups among various 
INR categories for low-intensity and high-intensity anticoagulation therapy were 
shown in Figures 4 and 5, respectively. 
Figure 4. Distribution of patient-years among the INR 
categories in the low intensity group 
2 5 (Target INR = 2-3, extended target I N R : 1.8-3.2) 
• Pharmacist group 
20 
• Physician group 
CD 15 I — 
^ I Jl 
C 





| | ] m 
0 • . : ： HJ-. H-l
 r
HiJ .. B-l , H>.L「a^ n . — — , 「 , ； - - - - ： 
0.1- 0.5- 1.0- 1.5- 2.0- 2.5- 3.0- 3.5- 4.0- 4.5- 5.0- 5.5- 6.0- 6.5- 7.0- 7.5-
0.4 0.9 1.4 1.9 2.4 2.9 3.4 3.9 4.4 4.9 5.4 5.9 6.4 6.9 7.4 7.9 
INR categories 
Figure 5. Distribution of patient-years among the INR categories 
in the high intensity group 
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Table 4 showed the control of INR of patients in both groups expressed in 
percentage of patient-time spent within the therapeutic range. The patients in the 
pharmacist-managed group spent 64% of time within the therapeutic INR range 
while those in the physician-managed group spent 59% of time within range. The 
pharmacist-managed group had a significantly higher percentage of patient-time 
spent within the therapeutic INR range when compared to the physician-managed 
group (p<0.001). Similar results were also obtained for the expanded therapeutic 
range. Patients in the pharmacist-managed group spent significantly more 
patient-time (78%) in the expanded therapeutic range than those in 
physician-managed group (76%) (p<0.001). 
When the patients with low-intensity and high-intensity anticoagulation 
therapy were examined separately, those in pharmacist-managed groups still 
consistently spent more patient-time in therapeutic range than those in 
physician-managed groups (64% vs 60% for low intensity anticoagulation therapy 
and 66% vs 44% for high intensity anticoagulation therapy, p<0.001). The pooled 
INR results from both groups showed that the 137 patients spent 61% of time in 
the therapeutic INR range and 77% of time in the expanded range. 
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Table 4. Control of INR 






 59% <0.001 
therapeutic INR range 
Patient-time (%) in 64<)/0 60% <0.001 
therapeutic range for the 
group with target INR of 2-3 
Patient-time (%) in 66% 44% <0.001 
therapeutic range for the 
group with target INR of 
2.5-3.5 
Patient-time (%) in
 7 8 %
 76% <0.001 
expanded therapeutic range* 
* Expanded therapeutic range = therapeutic range 土 0.2 INR units 
3.3 Incidence of major bleeding and thromboembolism 
The complication rates for both study groups are shown in Table 5. No 
patient had fatal events in the present study. There was no significant difference in 
both major bleeding and major thromboembolism between the two study groups. 
One patient from each group experienced transient ischemic attack (1.6 events per 
100 patient-years; p=1.00). Both patients were hospitalized and the symptoms 
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were resolved spontaneously. The INR at the time of event was not documented in 
both cases. One patient in the pharmacist-managed group experienced 
menorrhagia with anaemic symptoms at an INR of 2.39 during admission (1.6 
events per 100 patient-years) and two patients in the physician-managed group 
experience bleeding (one had extensive bruising with gross hemoptysis and 
INR>5 and one had peptic ulcer with iron deficiency anaemia; 3.1 events per 100 
patient-years) (p=1.00). 
Table 5. Complications of warfarin therapy 
Pharmacist-managed Physician-managed p value 
group group 
Number of Bleeding (number per 100 patient-years) 
Major 1(1.6) 2(3.1) 1.00 
Fatal 0 0 




Fatal 0 0 
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3.4 Direct medical cost analysis 
The mean cPPPM and its components are shown in Table 6. Clinic cost 
was the major component cost for both the physician and pharmacist managed 
service and it constituted over 50% of the total cost in both groups. Since warfarin 
is available as a generic drug, the medication cost was low. Although the 
hospitalization rates in both groups were low, the cost for hospitalization still 
constituted around 30% of the total cost in each study group. There were no 
significant differences in the mean cPPPM regarding medication use, emergency 
room utilization and hospitalization between the two study groups. The mean 
cPPPM for the pharmacist-managed clinic visit (USD46 土 35) was significantly 
lower than that for the physician-managed clinic visit (USD67 土 51) 
(1USD=7.8HKD) (p<0.01). The mean total cPPPM of the pharmacist-managed 
group was USD76 土 95 and it was significantly lower than that of the 
physician-managed group (USD98 土 158) (p<0.01). 
Since the pharmacist-managed service was experimental with no standard 
cost for its clinic visit, the cost per pharmacist-managed clinic visit was assumed 
to be 50% of that per physician-managed clinic visit in the base-case analysis. A 
sensitivity analysis was therefore conducted on the cost per pharmacist-managed 
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clinic visit over a range of 10%-100% of the cost per physician-managed clinic 
visit. The results of the sensitivity analysis showed that the total cPPPM of the 
pharmacist-managed group was significantly lower than that of the 
physician-managed group when the cost per pharmacist-managed clinic was 
10%-60% of the cost of physician-managed clinic. There was no significant 
difference in the total cPPPM between the two groups when the cost of 
pharmacist-managed clinic was 70%-90% of the physician-managed clinic. The 
pharmacist-managed group became significantly more costly when the cost of the 
pharmacist-managed clinic was the same as that of the physician-managed clinic. 
Table 6. Mean cost per patient per month (cPPPM) (USD)
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Pharmacist-managed group Physician managed p value 
group 
Clinic visit 46 土 35 67 ±51 <0.01 
Medication 2.7 ±1.6 2.6 ±1.1 0269 
Emergency room 1.0 士 2.7 1.0 ±4.0 0.195 
Hospitalization 26 土 91
 2 7 ± 1 4 5 0 > 1 0 2 
Total 76 ±95 98 ±158 <0.01 
a: U S D 1 = H K D 7.8 
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3.5 Patient satisfaction 
Table 7 showed the results of PSQ-18 survey grouped into 7 scales and 
also the overall mean score. Among the seven scales, the pharmacist-managed 
group had a mean score higher than 4 in 'interpersonal manner', 'technical 
quality，and 'communication'. In the physician-managed group, a highest score of 
3.84 was obtained for the scale of'general satisfaction'. 
Table 7. Results of PSQ-18 assessment 
Mean score (SD) P value 
Pharmacist-managed Physician-managed 
group group 
General satisfaction 3.98 (0.45) 3.84 (0.47) 0.134 
Technical quality 4.00 0.26) 3-83 0.35) 0.014 
Interpersonal
 4 Q 4 ( Q 3 6 ) 3
.74 (0.55) 0.003 
manner 
Communication 4.01 0.36) 3.68 0.59) 0.003 
Financial aspect 3.64 0.62) 3.63 0.73) 0.901 
Time spent 3.94 (0.42) 3.35 0.58) <0.001 
Accessibility 3.62 0.35) 3.33 0.40) <0.001 
Overall mean score 3.83 (0.22) 3.62 (0.29) <0.001 
4 8 
When the scores of the two groups were compared, there was no 
significant difference in the scores of 'general satisfaction' and 'financial aspect'. 
However, the scores for 'technical quality', 'interpersonal manner', 
'communication', 'time spent with clinician' and ‘accessibility and convenience' 
were significantly higher in the pharmacist-managed group. The overall mean 
score of the pharmacist-managed group was 3.83 ± 0.22 and that of the 
physician-managed group was 3.62 士 0.29. The pharmacist managed group had a 
significantly higher overall mean score when compared to the physician-managed 
group (p<0.001). When patients from both groups were pooled and analysed, 
there was no significant difference in the overall mean PSQ score between male 
and female patients. (p=0.57) 
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Chapter Four 
Discussion and Conclusion 
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4.1 Discussion 
The present study was the first randomized clinical trial comparing the 
clinical, economic and humanistic (patient satisfaction) outcomes of a 
pharmacist-managed anticoagulation service with those of a physician-managed 
anticoagulation service. In the present study, the Chinese patients in the 
pharmacist-managed group had a better INR control as reflected by a higher 
percentage of patient-time spent in the therapeutic (64% vs 59%) and the 
expanded therapeutic (78% vs 76%) INR ranges when compared to the 
physician-managed group and the difference achieved statistical significance. The 
mean cPPPM was significantly reduced by 22% (USD98 in the 
physician-managed group versus USD76 in the pharmacist-manage group). 
Patients were more satisfied with the service offered by the pharmacist than that 
offered by the physicians as reflected by a significantly higher overall mean score 
forthePSQ-18(3.83 vs 3.62). 
Anticoagulation clinic is a systematic way, using specially trained 
personnel, to manage anticoagulation therapy. Its purposes are to optimize the 
delivery of anticoagulant therapy to patients, and to provide the best quality of 
care to improve clinical outcomes through a coordinated approach. Coordinated 
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anticoagulation care has been endorsed by the A C C P to be a primary approach in 
the management of warfarin therapy and it has also been accepted as the model of 
care in the United Kingdom and in the Netherlands. Physicians, pharmacists and 
nurses, if properly trained, can all be providers of an anticoagulation service. 
Though this model of care is widely implemented in the western countries, it is 
still a relatively new concept in Hong Kong. Most of the patients in Hong Kong 
are still managed by the R M C model. In our study, both the pharmacist-managed 
clinic and the physician-managed clinic were operated as a coordinated 
anticoagulation service and both clinics achieved good control of INR and low 
complication rates. When INR results from both groups were pooled together, the 
137 patients achieved high-quality anticoagulation control of 61% and 77% of 
patient-time spent in the therapeutic and the expanded therapeutic INR ranges 
respectively. The rates of bleeding and thromboembolism were found to be 
1.6-3.1% and 1.6% respectively. 
4.1.1 Clinical Outcomes of Anticoagulation Clinic 
The model of care provided by the A C is associated with better clinical 
outcomes than the R M C . Chiquette et al conducted a retrospective study to 
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compare newly anticoagulated patients who were treated in the R M C with those 
treated at an A C for anticoagulation control, bleeding and thromboembolic events 
and the difference in cost for hospitalization and emergency department visits. 
(Chiquette E et al 1998) Their analysis included 176 patients (with 123 
patient-years) in the A C group and 142 patients (with 102 patient-years) in the 
R M C group. They found that patients spent 40-64% of time within the therapeutic 
range for the A C group and 37-51% of time within the same target range for the 
R M C group. In our study, a total of 137 patients (126 patient-years) spent 61% of 
patient-time within the therapeutic range. Our findings were in consistence with 
the INR control in the A C group reported by Chiquette et al. 
Chiquette et al also reported that bleeding rates were 1.6% in the A C group 
and 3.9% in the R M C group. The overall bleeding rates found in our study 
(1.6-3.1%) were comparable to that found in their A C group and lower than that 
found in their R M C group. In our study, thromboembolism occurred at a 
frequency of 1.6%. This was also in consistence with the rate found in their A C 
group (3.3%) and much lower than that found in their R M C group (11.8%). 
Garabedian-Ruffalo et al looked into the effectiveness of a 
pharmacist-managed A C by comparing the clinical outcomes of patients before 
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and after clinic enrolment. (Garabedian-Ruffalo S M et al 1985) Retrospective 
chart reviews were performed for 26 patients. The preclinic phase (before referral 
to the AC) consisted of 64.3 patient-years while the clinic phase consisted of 41.9 
patient-years. The percentage of prothrombin times within the expanded 
therapeutic range (64% versus 75%) was significantly lower during the preclinic 
phase than during the clinic phase. Our result of 77% of patient-time within the 
expanded therapeutic range was in consistence with the INR control found in their 
clinic phase and our patients also had a better INR control when compared to their 
patients in the preclinic phase. 
As reported by Garabedian-Ruffalo et al, eight patients (12.4%) were 
hospitalized for hemorrhagic complications and four (6.2%) for thromboembolism 
during the preclinic phase. Only one (2.4%) hospitalization for hemorrhage 
occurred during the clinic phase. Our findings showed similar rates of 
complications (1.6-3.2%) to those of their clinic phase. 
Wilson et al conducted a randomized controlled trial to evaluate the 
outcomes when patients on warfarin were managed in a pharmacist-managed A C 
versus by family physicians (RMC). (Wilson SJ et al 2003) All patients were 
followed over a 3-month period. Of the 221 patients enrolled, 112 were randomly 
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allocated to the A C and 109 to the R M C . They found that the INRs of patients 
managed in the A C were in the therapeutic range 63% of the time and the 
expanded therapeutic range 82% of the time. For those patients that were allocated 
to the R M C , their INRs were in the therapeutic range 59% of the time and the 
expanded therapeutic range 76% of the time. Our results of 61% of the time 
within the therapeutic range and 77% of the time within the therapeutic range 
were in consistence with those reported in the A C group by Wilson et al. 
Wilson et al reported that the rates of major bleeding and 
thromboembolism were 2% and 1% respectively in the A C group. These findings 
were also comparable to our findings (1.6-3.1% for major bleeding, 1.6% for 
thromboembolism). 
The results of our study, as a randomized, controlled trial, add strength to 
the level of evidence supporting improved INR control in the pharmacist-managed 
A C than the physician-managed AC. Several reasons may account for the 
improvement in the pharmacist-managed group. The clinical pharmacist in the 
pharmacist-managed group provided intense education to the patients and their 
caregiver from time to time and it might improve patient knowledge on the 
importance of blood check and regular follow-up, the signs and symptoms of 
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bleeding and thromboembolism and the precautions when taking warfarin. The 
clinical pharmacist also checked patients' adherence more thoroughly, especially 
for those with advanced age, with poor memory and with questionable 
compliance. 
The clinical pharmacist, as a drug expert, provided extra attention to the 
potential warfarin-drug, warfarin-herb and warfarin-supplement interactions at 
each clinic visit so that adverse consequences of drug interactions can be promptly 
identified. In the present study, telephone follow-ups were conducted by the 
clinical pharmacist for those patients with poor adherence or difficult INR control 
to check if they had any problems on warfarin therapy at home. A hotline 
telephone was available to the patients to inquire about any warfarin-related issues 
in between their clinic visits. Better patient satisfaction with the service offered by 
the pharmacist may also motivate the patient and improve their self-control and 
adherence to warfarin therapy. All these may contribute to the improved INR 
control in the patients managed by the clinical pharmacist. 
4.1.2 Direct medical cost analysis 
In our study, the mean total cPPPM was 22% lowered in the 
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pharmacist-managed clinic when compared to the physician-managed clinic and 
this difference achieved statistical significance. The improvement in INR control 
with cost-saving in the pharmacist-managed group was consistent with the 
published studies overseas which evaluates the cost-effectiveness of 
pharmacist-managed anticoagulation service. 
Lafata et al constructed a 5-year Markov model to evaluate the health and 
economic outcomes associated with each of three different anticoagulation 
management approaches: R M C , A C and patient self-testing using information 
available in the scientific literature, supplemented with data from their local 
institution and expert opinion. (Lafata JE et al 2000) They found that 1.7 
thromboembolic and 2.0 hemorrhagic events could be avoided per 100 patients 
over 5 years when moving from the R M C to the AC. The A C was the most 
cost-saving among the 3 models of care from the perspective of medical care 
provider. A potential saving of USD13954 per 100 patients over 5 years could be 
achieved when patients were moved from the R M C to the AC. This saving was 
mainly due to a reduction in the number of complications when patients were 
managed in the AC. 
Chiquette et al also compared the cost between the A C and the R M C groups. 
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(Chiquette E et al 1998) They found that hospitalization and emergency 
department visits were reduced by 73% when patients were managed in a 
pharmacist-managed A C instead of the R M C , yet the cost of routine clinic visit 
was not documented in their study. The annual cost saving was U S D 128,937 per 
100 patients enrolled. 
Wilt et al conducted a retrospective chart review on patients who received 
warfarin therapy to determine the cost-effectiveness of a pharmacist-managed 
anticoagulation service when compared to the R M C . (Wilt V M et al 1995) They 
identified 68 patients with 60 patient-years in the A C group and 28 patients with 
44 patient-years in the R M C group. It was estimated that there would be a 
potential cost avoidance of USD4073 per patient-year of follow up if patients 
were managed in the A C instead of R M C . This was mainly due to a lower rate of 
complications (0 events in the A C group vs. 17 events in the R M C group) when 
patients were managed in an AC. 
In the above overseas studies, ACs were shown to reduce the overall 
healthcare cost and were cost-effective when compared to the R M C . The cost 
saving was mainly due to lower rates of complications that required 
hospitalization or emergency department visits. In our study, both groups were 
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operated as coordinated anticoagulation services and the rates of complications 
and hospital admissions were low. However, the pharmacist service was shown to 
be more cost-effective than the physician service in our study. The cost-saving 
was mainly due to the decreased running cost of the clinic visits in the 
pharmacist-managed group. Sensitivity analysis showed that the 
pharmacist-managed service became more costly if its cost of clinic visit was the 
same as that of the physician-managed clinic because of the more frequent 
follow-ups in the pharmacist-managed group according to the management 
protocol. The pharmacist service was shown to be more cost-saving because there 
was a substantial difference in salary between a clinical pharmacist and the 
medical staff and that the salary of the health care professionals is the major cost 
component of the routine clinic visit. The point-of-care testing cost 40% more 
than the laboratory INR assay. If both study groups used the point-of-care testing, 
it would further increase the cost-saving of the pharmacist-managed group 
comparing to the physician-managed group. 
4.1.3 Patient satisfaction 
Besides clinical effectiveness and cost issues, patient satisfaction is gaining 
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increasing attention in clinical practice nowadays. Lodwick et al evaluated patient 
satisfaction of a pharmacist-managed A C using a questionnaire consisting of nine 
Likert statements with choices ranging in value from 1 (strongly disagree) to 5 
(strongly agree). (Lodwick A D et al 2000) A total of 34 questionnaires were 
successfully returned and analysed. It was found that patient generally had high 
satisfaction with the pharmacist-managed clinic as reflected by a score of over 4 
in 8 out of the 9 questions. They were especially impressed with 'use of 
fingerstick' (4.88), 'appointment on time' (4.82), 'trust the pharmacist' (4.79) and 
'adequate time during appointment' (4.73). In our study, the pharmacist-managed 
clinic, which also used finger-pricking, also had similar findings that patients 
thought the pharmacist spent adequate time with them, the pharmacist was 
technically competent and could be trusted, and it was convenient to follow-up in 
the clinic without the need to wait for too long. 
Wilson et al also compared patient satisfaction between the A C and the R M C 
group. (Wilson SJ et al 2003) They used a previously validated questionnaire 
consisting of 10 items to evaluate patient satisfaction and the questionnaire was 
completed at the end of the 3-month follow-up period. They found that 96% of 
patients were satisfied or very satisfied with the service offered by the pharmacist, 
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while only 84% of patients felt the same for the physician service (p=0.001) 
Patients in the A C reported that they were more satisfied with 'teaching', 
'helpfulness of staff', 'availability of staff in an emergency' and 'time spent with 
staff' compared with the R M C group. This was in consistence with our findings 
that patients in our pharmacist-managed clinic were more satisfied with 'time 
spent', 'accessibility' and 'interpersonal manner' when compared to the 
physician-managed clinic. 
Patient satisfaction is an important issue because it can affect the outcomes 
of therapy, especially for those with chronic diseases. (Kirsner RS et al, 1997) A 
more satisfied patient is less likely to miss appointments and is expected to have 
better compliance. Moreover, the patient may also be more proactive in his or her 
own management of the disease. The most frequently reported complaints of 
patients concerning out-patient care were 'poor manner of provider', 'provider not 
listening to them', 'short consultation time' and 'long waiting time'. (Hill J 1997) 
In our study, the pharmacist-managed clinic scored high in all these aspects in the 
PSQ-18. Patients were especially impressed with 'time spent' and 'accessibility' 
in our pharmacist-managed service. This may be because thorough questions were 
asked at each consultation and intense patient education was provided from time 
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to time, making patients felt that there was adequate time for them to discuss with 
the pharmacists on their problems and concerns. Moreover, a phone line was 
available for accessing pharmacist consultation and walk-in appointments were 
usually available in case of emergency. All these made the pharmacist-managed 
clinic more accessible and convenient when compared to the physician-managed 
clinic. 
4.1.4 Limitations 
There are several limitations in our study. In the pharmacist-managed group, 
there were significantly more female patients than the physician-managed groups 
(65% versus 45%, p=0.031). Fihn et al had looked into the risk factors for 
complications in patients on chronic warfarin therapy and he found that the 
relative risk for a first time serious bleeding event was 1.9 (95%CI = 1.3-3.0) 
times greater in women than in men even after intensity of treatment was 
adjusted. This higher risk of bleeding in women was mainly due to vaginal or 
uterine bleeding. (Fihn SD et al, 1993) Yet, the bleeding rate found in the 
pharmacist-managed group was not higher than that of the physician-managed 
group in our study. The present sample size in our study did not provide enough 
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power to detect the difference in incidence of complications between the study 
and control groups. A larger number of patients and a longer duration of study 
would be required. Nevertheless, the present sample size provided adequate 
power to detect the difference in the percentage of patient-time in target INR 
ranges, total direct medical cost as well as patient satisfaction. 
Despite the fact that the survey administrator of PSQ-18 was not an 
investigator of the present study, she was not blinded to the patient allocation 
since the two clinics were scheduled at different times and at different locations. 
Thirdly, the actual "time spent" by the pharmacist or physician for clinic visits in 
the two groups were not captured in our study. A sensitivity analysis was 
therefore included to examine the variation of cost of clinic visit that might arise 
due to different "time spent" in the two groups. Moreover, the capture of 
complications may not be completed since it depended on self-reporting by the 
patients. However, the investigator did check the computerized patient profile on 
a regular basis to capture events that were not reported by the patients 
4.1.5 Future studies 
There are a number of opportunities remained for future studies on the 
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management of anticoagulation therapy by pharmacists. Since the present study is 
not powered to detect the difference in complications between the two study 
groups, a study with a longer duration and more patients can be carried out to 
evaluate the long-term impact of a pharmacist-managed clinic and investigate if 
the improved INR control can translate to a reduction in the complication rates. In 
our study, the cost analysis was from the perspective of the medical care provider 
and only direct medical cost was taken into account. The analysis can be further 
expanded to include not only the cost incurred by the medical care providers but 
also that by patients and their caregiver (e.g. time cost, travel cost) in the receipt 
of such care to see if the pharmacist-managed anticoagulation clinic is still 
cost-saving from this societal perspective. 
Moreover, with the use of the point-of-care device in the management of 
warfarin therapy, the setting of care is not restricted to clinics anymore. 
Community pharmacists may also be involved in checking the INRs for patients 
on warfarin in between clinic visits and the results can be fed back to the 
anticoagulation clinic for further management. An outreach service may also be 
set up so that the clinical pharmacists can conduct home visits for INR monitoring 
for those patients with advanced age or who are less ambulatory. 
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Besides outpatient anticoagulation services, pharmacists can also be involved 
in the anticoagulation care for hospitalized patients. In-patient 
warfarin-monitoring service implemented by clinical pharmacists was shown in 
other countries to improve warfarin dose determination, improve INR stability at 
hospital discharge and increase the number of therapeutic INRs at the first clinic 
visit. Such service, which aims at further improving the outcomes of warfarin 
therapy, can also be implemented and investigated in Hong Kong public hospitals 
to see if similar benefits can be obtained. (Ellis RF et al 1992) 
With the demonstration of pharmacist-managed care model for management 
of chronic warfarin therapy, using a carefully designed management protocol, 
clinical pharmacists can also serve as a primary care provider for other chronic 
illnesses such as hypertension, diabetes mellitus, hyperlipidaemia and asthma. 
Such pharmacy-managed clinics have been shown in other countries to improve 
the outcomes of patients (Jaber L A et al 1996, Okamoto M P et al 2001, Leal S et 
al 2004) and should be given trials in Hong Kong to see if it is feasible and to 
investigate if similar benefits can be obtained. 
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4.2 Conclusion 
In conclusion, our study has demonstrated that a management model for 
anticoagulation therapy, including a pharmacist as the primary care provider with 
physician consultation for predetermined conditions, was more effective and less 
costly than a model of care solely managed by physicians in achieving target INR 
control for Chinese patients on warfarin therapy. Patients were more satisfied with 
the anticoagulation service provided by the pharmacist than the 
physician-managed anticoagulation service. Currently, this is the only 
pharmacist-managed anticoagulation clinic in Hong Kong. The results of the 
present study support the implementation of this model of care for anticoagulation 
management at other hospital settings in Hong Kong. 
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Appendix A 
Recommended Therapeutic Range for Oral Anticoagulant 
Therapy 
Indications INR 
Prophylaxis of venous thrombosis 2.0-3.0 







Prevention of systemic embolism 2.0-3.0 
> Tissue heart valves 
> A M I (to prevent systemic embolism)* 
> Valvular heart disease 
> AF 
Mechanical prosthetic valves (high risk) 2.5-3.5 
Bileaflet mechanical valve in aortic position 
* If oral anticoagulant therapy is elected to prevent recurrence MI, an INR of 2.5-3.5 is 
recommended, consistent with US Food and Drug Administration recommendations. 
Note: 
1. An INR of > 1.5 confers some benefits in patients with AF, although the benefit is clearly 
less than that which occurs with an INR > 2.0. 
2. The clinical outcomes are improved when the therapeutic range for patients receiving lupus 
anticoagulants is closer to 2.5-3.5 rather than 2.0-3.0. 
Reference: Chest 2001; 119:8S-21S 
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Appendix A 
Situations that require physician's attention: 
> INR >4.5 
> Patient who intends to undergo dental or other operations 
> N e w neurological signs and symptoms 
> Melena stool, hematuria 
> Active bleeding 
> Shortness of breath, leg swelling suggestive of recurrent PE/DVT 
> Completion of intended course of treatment, to determine whether 
treatment should be continued or not 
> INR failed to reach therapeutic range after 3 visits 
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Appendix A 
Dosage Adjustment Tables 
1. Low Intensity (Target INR=2-3) 
1 丨 l l 】 1 3.21 4 I 
• — ^ “ Off 1 day, then 
| l 2 丨 1.5 I 1.25 丨 1 0.75 0.5 一 
1 1 9S _ 1 - 2 5 ！ ！ 
• T f Z25~" 2 1 
I 1.75 2 i 5 ~ " _ _ _ 2 _ _ _ _ 2 _ _ U 5 L^ 
2 " 5 2 . 5 _ _ _ 2 : 2 5 _ 2 1-75 。 
1 ^ 2 5 ？ ？ 
f f f 3 3 ~ Z _ _ r 7 5 _ _ 2.5 2.25 2 
• f f 5 2,5 ^ 
• 3 2,5 
• 3.25 3.75 3 J 3 . 5 3.25 3 ? 
4 3 
3.75 . 4.25 — 4 4 3J5 ^ ^ 
mm — 
M T 2 5 4 4 
^ 9 ^ 5 sZZ—^— 4.5 4 2 5 4 
翻 5.25 5“―“ 5 4.75 4,5 ^ 
• ; "~5 J 5 
國 5.25 6.25 5.5 _ _ ^ ？ 5 
“ A — 6 5.5 525 5 
B 5.75 6.75 6 6 __5J5 5,5 
• 6 — 7 __ 6 5J5 575 
1 I 6.25 ^ ^ 
• 6 5 7 5 7 ‘ 6.75 6.5 625 6 I 6.75 ^ ^ 
W J ^ 8 5 — 8 7.25 7 ^ ^5 
^ ^ — 
I 7.5 9 8 7.5 _ _ _ 7 _ _ 1 
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Appendix A 
2. High Intensity (Target INR=3-3.5) 
j y s ^ i m * 3 5 1 4 1 
“ Off 1 day, then 
M l 2 1.5 1.25 1 0.75 — 0.5 
M i 1.25 2 1.5 _ _ ！ ！ 
圓 1:5 — 2.25 2 1.75 _ _ L ^ 1 
Z 2 5 ~ ~ 2 . _ _ L ? L ? 
_ 2 2.5 2.5 — 2.25 2 1.75 
W m 2.25 2.75 2.5 2 J 2 2 5 ? ? 
P | 2,5 3 3 2 
議 2.75 ~ T 2 5 ~ ~ 3 3 2 J 5 ^ g 
• j 3.5 3.5 “ 3 , 2 5 _ _ _ _ 3 _ _ _ _ ^ Z 5 ^ 
l a 3.25 3.75 3.5 ？ ？ 
3.5 4 4 3.5 ^ 2 5 3 
3,75 “ 4.25 4 4 _ A Z 5 3,5 ^ 5 
4 4 5 4.5 4.25 4 3 J 5 3,5 
H 4.25 4.75 4.5 — 4 4 
5 4 
國 ： “ 5 T Z — i ^ j 4,5 4,5 
B 5 5.75 5.5 — 5 j 5 _ _ _ _ _ l _ _ — 
B a 5.25 “ 6.25 5.5 A ^ g ？ 
• 6.5 6 — _6 5j 525 5 
_ 5:75 6.75 6 6 _ _ 5 J 5 ^ 绘 
P J 6 7 7 6.5 6 5,75 5H5 
| H 6.25 _ 7.25 6.75 _ ^ \ 
6:5 7 5 — 7 6.75 6.5 625 6 
B l | 6 J 5 ~ ~ 8 ~ 7.5 H Z — ^ ^ 
8.5 ~ ~ 7 — " ^ ^ 
M 7.25 "8?75 8 ~ ~ ^ ^ 
圓 7.5 I 9 丨 8 I _ _ 1 _ _ 1 
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Appendix A 
Suggested Follow-up Intervals: 
> A follow-up interval of 2-4 weeks is suggested for patients with 
Recent adjustment in warfarin dosage 
Recent change in medications that may interact with warfarin 
INR outside suggested therapeutic range 
> For patients with INR results within the therapeutic range, the 
follow-up visits can be scheduled after 8-10 weeks. 
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Appendix A 
Contraindications to Oral Anticoagulant Therapy 
> Active bleeding 
> Hemophilia or other hemorrhagic tendencies 
> Severe liver disease with elevated baseline prothrombin time (PT) 
> Severe thrombocytopenia (platelet count < 20 000) 
> Malignant hypertension 
> Inability to meticulously supervise and monitor treatment 
> Hypersensitivity to warfarin 
> Pregnancy 
> History of warfarin-induced skin necrosis 
Reference: Pharmacotherapy A Pathophysiologic Approach 5,h Edition, McGraw Hill 
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Appendix A 
Risk Factors for Major Bleeding while Taking Oral 
Anticoagulant 
> Anticoagulation intensity (e.g. INR > 4) 
> Initiation of therapy (first few days and weeks) 
> Unstable anticoagulation response 
> Age > 65 years 
> Concurrent antiplatelet drug use 
> Concurrent nonsteroidal anti-inflammatory drug (NSAID) use 
> History of gastrointestinal bleeding (GIB) 
> Recent surgery or trauma 
> High risk for fall/trauma 
> Heavy alcohol use 
> Renal failure 
> Cerebrovascular disease 
> Malignant cancer 
Reference: Pharmacotherapy A Pathophysiologic Approach 5th Edition, McGraw Hill 
-10-
Appendix A 
Medical conditions that may alter INR response 
> Blood dyscrasis 
> Cancer 
> Collagen vascular disease 
> Congestive heart failure 
Conditions that may � � , 
> Diarrhea 
increase INR response > 日evated temperature 
> Hepatic disorder (infectious hepatitis, jaundice) 
> Hyperthyroidism 
> Poor nutritional state 
> Steatorrhea 
> Vitamin K deficiency 
I ——: 
> Edema 
Conditions that may > Hereditary resistance 
increase I N R response > Hypei lipemia 
> Hypothyroidism 
> Nephrotic syndrome 




j > The number in the bracket indicates the significance rating of the interaction from j 
j Drug Interaction Facts, Facts & Comparisons^ ！ 
j Sig. Rating Severity Documenation — j 
j J Major Suspected or > j 
； 2 — Moderate Suspected or > j 
j ~~3 Minor “ Suspected or > j 
j 4 Major/Moderate Possible j 
j ~5 Minor Possible j 
I Any _ Unlikely j 
j > The more significant interactions (rating 1 or 2) are in bold. j 
1. Decrease Anticoagulation Effects (U INR response) 
^ H S ? ^ ^ • Estrogens � • Aluminum h y d r o x y • Ethchlorvynol (4) 
• Ca rbamazcp ine (2) • Oral contraceptives • Cholestyramine* ⑵ •『肌,，(2) 
• Glutethimide (2) • Vitamin K (including • Colestipol* • Spironolactone- (5) 
• Griseofulvin (2) nutritional supplements) • bucraitate p ) 
• Nafcillin (4) � 
• Phcnytoin (2) 
• Rifampin (2) 
“ l _ L 
^Cholestyramine and colestipol may increase the anticoagulant effect by binding vitamin K in the 
gut; yet, the decreased drug absorption appears to be of more concern. 
^Diuretic-induced hemoconcentration with subsequent concentration of clotting factors has 
been reported to decrease the effects of oral anticoagulants. 
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2. Enhanced Anticoagulation Effects ( ft INR response) 
• Oral antibiotics • Chloral hydrate (3) •Allopurinol (4) • Acetaminophen (5) 
can increase or . Clof ibrate (1) •Amiodarone (1) • Anabolic steroids 
decrease INR. • Diazoxide .Azole antibiotics (1) • Capecitabine 
Check INR 3 days • Ethacrynic acid •Capecitabine • Celecoxib (4) 
after patient . Miconazole (including •Chloramphenicol (2) • Clarithromycin (1) 
begins antibiotics intravaginal use) (1) •Chlorpropamide • Clofibrate (1) 
to see the INR • Nalidixic acid (2) •Cimetidine (1) • Danazol ( l ) 
value and adjust • Phenylbutazone (1) •Ciprofloxacin (4) • Erythromycin (1) 
the warfarin dose • Salicylates (1) .Co-trimoxazole (1) • Gemfibrozil (1) 
accordingly. . Sulfonamides (1) .Disulfiram (2) • Glucagon (2) 
• Sulfonylureas .Ethanol (acute ingestion)+ (4) • Influenza vaccine (5) 
• Flutamide • Propranolol (4) 
• Isoniazid (4) • Propylthiouracil (1) 
•Metronidazole (1) • Ranitidine 
•Norfloxacin (4) • Rofecoxib (4) 
• Ofloxacin (4) • SSRIs (4) 
• Omeprazole (4) • Sulindac (2) 
• Phenylbutazone (1) • Tetracycline (4) 
•Phenytoin (2) • Thyroid drugs (1) 
• Propafenone (4) • Vitamin E (>400 IU) 
•Propoxyphene(4) � 
• Quinidine (1) 
• Statins^ (2-4) 
• Sulfinpyrazone (5) 
• Sulfonamides (1) 




'The hypopwthrombinemic effect oforal anticoagulants has been reported to be both increased 
and decreased during chronic and excessive alcohol ingestion. Data are insufficient to predict the 
direction of this interaction in alcoholic patients. 




3. Increased Bleeding Tendency (INR may or may not be changed) 
^ S S S ^ 8 ™ ™ ™ . Antimetabolites (2) • Adrenal corticosteroids (4) 
• Clopidogrel • Quinidine(l) • ^ 0 7 , 7 ( 2 ) 
• Dipyridamole • Q — � • „ „ ” 
. I n d o m e t h a c i n ( 2 ) • Salicylates � • ^一 b u t a z o n c 1) 
, . x • Potassium products 
• Oxyphenbutazone( l ) Salicylates (1) 
. P e n i c i l l i n (parenteral) (2) Salicylates (1) 
• Phenylbutazone (1) 
• Salicylates (1) 
• Sulfinpyrazone (5) 
• Ticlopidine 
Use of these agents with oral anticoagulants may increase the chance of hemorrhage. 
Reference: 
1. Drug Information Handbook, Lexi-Comp 
2. Drug Interaction Facts, Facts & Comparisons Division, J.B. Lippincott 
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Appendix A 
OTC Drugs to Avoid when Taking Warfarin 
> Include aspirin, ibuprofen and cimetidine 
OTC drugs which contain aspirin (or salicylates) 
TRADE NAME MANUFACTURER 
A p C TAB ~~ KAREN LAB 
2 ALKA-SELTZER TAB 一 B A Y E R C H I N A C 0 L T D 
~ A N A C I N T A B W Y E T H ( H K ) L T D _ _ 
I ~ ASPI-COR ENTERIC COATED TAB 81 MG JULIUS CHEN & CO (HK) LTD 
5 ASPILETS TAB 80MG U N A M C 0 R P Q R A T I Q N L T D 
~ ASPRO CLEAR TAB 300MG SOLUBLE ROCHE HONG KONG LIMITED 
— A S P R O TAB 300MG ^ Q C H E H Q N G K 0 N G U M ' T E D 
" i B O K E Y F M T F P r M r p n ^ N i r A P . Q i il ATFH CAP100MG YUNG SHIN CO LTD—— 
— B U F F E R I N TAB BR.STOL-MYERS SQU.BB (HK) LTD —— 
CARDIPRIN 100 TAB 100MG ^ C K I T T BENCK.SER HONG KONG LTD 
I I CARTIA TAB ENTERIC COATED 100MG GLAXOSMITHKLINE L I M I T E D — — 
— C H E P H A P Y R . N N TAB S C E N T S PHARMA TRADING CO LTD 
— C O L D E N I N CAP 从丨 丫UEN PHARMACEUTICAL CO 
— C Q R T A L TAB FOR ADULTS GLAXOSMITHKLINE LIMITED 
I ? - DISPR.N D.RECT CHEWABLE TAB 300MG 一 ^ C K U T BENCK.SER HONG KONG L T D — — 
f DISPR.N TAB 300MG ^ RECKITT BENCKISER HONG KONG L T D — — 
— D O L O X E N E COMPOUND 100 CAP ^Ll LILLY ASIA INC (HK BRANCH) 
I T " DOPOXY CO-32 CAP, CO-65 CAP C H R I S T Q P H A R M L T D , , , 
— E C O T R I N TAB 650MG ENTERIC COATED GOLDSH丨ELD (HONG KONG) LTD 
ESP.N TAB 200MG C 0 N N Q R P H A R M M | , 
？1 EXCEDRINTAB BRISTOL-MYERS SQUIBB (HK) LTD 
I f - U ^ N E M CAP 100MG 二 H.TPHARM PHARMACEUTICAL CO L T D _ 
力 r | y p r i m t a r DRAGON LINK (INT'L) TRADING CO LTD 
A3 bL i r rm iN imp — H , p S _ G PHARM & TRADING LTD 
24 KOKKIN CAPSULE A CAP H I K r n M m v i —— 
oc LASPR1N100EC TAB 100MG LIFETECH (ASIA) LTD 
I F 二 = S M 0 L C H = = T A B KONG) L.M.TED - P H A r B ^ 
I T - PROPIRIN ENTERIC COATED TAB 100MG CHRISTO PHARM LTD 
i QUALITEA TAB 100MG B.C. Q U A L I T Y P H A R M L A B L_T° 
i SOLGESIC TAB 300MG U N I V E R S A L P H A R , M : 二 , , , 
STEN 2/LAYER TAB 队丨 YUEN PHARMACEUTICAL CO 
TESMIN PB CHEWABLE TAB SATO PHARM (HK) CO LTD 
32 UNI-ACETIL TAB 75MG. 300MG UN 丨 VERSAL PHARM LABLTD 
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OTC drugs which contain cimetidine 
" 1 TRADE NAME MANUFACTURER 
1 AGLUCINE 200 TAB 200MG MARCHING PHARM LTD 
2 AGLUCINE FORTE 400,400MG MARCHING PHARM LTD 
T ~ ALTRAMET TAB 200MG, 400MG — HIND WING CO LTD 
~ A B E L L A S E D 400 TAB 400MG UNICORN LAB 
BIGACONTAB200MG YUNG SHIN CO LTD 
— B R U M E T I D I N A TAB 400MG SHERATON WORLDWIDE DRUGS CO LTD 
CEMENTIN TAB 200MG — HAW PAR BROTHERS INTERNATIONAL (HK) LTD 
1 C I M E C O N T A B 2 0 0 M G WELL FAVOURED LTD 
1 C I M E D I N T A B 2 0 0 M G . 4 0 0 M G ADVANCE PHARM CO LTD 
10 CIMEDINE400TAB400MG ‘ P R I M A L CHEMICAL CO LTD 
~ CIMEDINETAB400MG . CHRISTO PHARM LTD 
~ | 2 C I M E D I N E - 2 0 0 TAB 200MG CHRISTO PHARM LTD 
I T C I M E L D I N E T A B 4 0 0 M G " " " UNITED ITALIAN CORP (HK) LTD 
I T CIMETA TAB 200MG, 400MG JEAN-MARIE PHARMACAL CO LTD 
1 5 C I M E T A B 200 TAB 200MG, 400 TAB 400MG MERCK APOTEC LTD 
1 6 C I M E T A X 200 TAB 200MG, 400 TAB 400MG MERCK APOTEC LTD 
17 CIMETIDIN 200, 400, 800 STADA TAB HONG KONG MEDICAL SUPPLIES LTD 
~ f j ~ CIMETINE TAB 200MG (TAIWAN PATRON) SAMUEL PHARM CO LTD 
i CIMULCERTAB200MG,400MG “ GREAT EASTERN HEALTHCARE LTD 
i CITIDINETAB200MG.400MG ATLANTIC PHARM LTD 
T T DEFENSE TAB 400MG YUNG SHIN CO LTD 
200MG WELL FAVOURED LTD 
~23~ EVAMET CAP 200MG UNICORN LAB 
~2A~ GASTAB 200 TAB 200MG, 400 TAB 400MG MERCK APOTEC LTD 
~25~ GASTIDINE-200 TAB, 400 TAB ViDA LAB LTD 
— n - . c T . n r . M P t a p . n n M H “ EURQPHARM LAB CO LTD 
GINOMIN TAB 200MG, 400MG NEOCHEM PHARM LAB LTD 
~28~ HEALING-U TAB 400MG UNICORN LAB 
~29~ HONTIDIN TAB 200MG, 400MG KAREN LAB. 
i HQUWEMINGTAB200MG HITPHARM PHARMACEUTICAL CO LTD 
31 LOTIDINETAB200MG LOYAL ADVANCE LTD 
32 LYCOSTOMIN TAB 200MG LOYAL ADVANCE LTD 
33 MAGICUL 200 TAB 200MG, 400 TAB 400MG 山E N CHEONG HONG LTD 
~34~ MARITIDINE 200 TAB 200MG, 400 TAB 400MG MARCHING PHARM LTD 
" i i " MAROOM STOMACH TAB 400MG WAH YAN HONG CHEM F T Y _ 
MARTINDALE TAB 400MG UNICORN LAB 
37 MEGADINTAB400MG MEDIPHARMA LTD 
NEUTRONORM RETARD TAB 350MG — HEALTHCARE PRODUCTS LTD 
" i i " NEUTRONORM TAB 200MG, 400MG HEALTH CARE PRODUCTS LTD 
40 NEW KREWAN 200, 400 TAB FILM COATED VIDA LAB LTD 
~ 4 1 N U L C E R TAB 200MG, 400MG NICE LAB LTD 
7 T NURQD1N.NJ150MG/ML L.NKLANDS TRAD.NG COMPANY 
I T NURQDINTAB400MG 
44 PALLIA 400 TAB 400MG _ _ 
To be continued on next page 
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TRADE NAME MANUFACTURER 
~45~ PRQTIDINE-200, -400 TAB FILM COATED VIDA LAB LTD 
1 6 ~ SHINTAMET F.C. TAB 400MG — YUNG SHIN CO LTD 
47 SIGMETADINE TAB 200MG, 400MG TREASURE MOUNTAIN DEVELOPMENT CO LTD “ 
I T SIMAGLEN TAB 200MG, 400MG HEALTH ALLIANCE INTERNATIONAL CO LTD 
49 STOGAMETTAB 200MG WILCOME PHARM CO LTD _ 
50 STOMCAP-1 TAB 200MG LOYAL ADVANCE LTD 
T T SUPER STOMACH-2 TAB 200MG ~ LOYAL ADVANCE LTD 
~ 5 2 S Y N C O M E T TAB 400MG — SYNCO (HK) LTD 
53 TAGADINE TAB 200MG, 400MG WESTON PHARMACEUTICAL LIMITED 
54 TAGAMET TAB 200MG, 400MG, 800MG GLAXOSMITHKLINE LIMITED 
"55" TAGMETIN CAP UNICORN LAB 
"56~~TAKAME TAB 400MG KAREN LAB. 
~ S T TALADINETAB400MG MEYER PHARM LTD 
TALAMIN FORTE TAB 400MG MEYER PHARM LTD 
"59 " TAMEDINFCTAB400MG “ KAI YUEN PHARMACEUTICAL CO 
" i T TIMET 200 TAB 200MG, 400 TAB 400MG — UNIVERSAL PHARM LAB LTD 
61 TOBETIDINE TAB 200MG, 400MG EUROPHARM LAB CO LTD 
62 UCIDINE TAB 400MG EUROPHARM LAB CO LTD 
" i T ULCERGENTAB200MG.400MG NEOCHEM PHARM LAB LTD 
64 ULCERINTAB200MG,300MG,400MG QUALITY PHARM LAB LTD 
65 ULCERMETTAB 200MG, 400MG UNIVERSAL PHARM LAB LTD 
66 U L C I M E T A B 4 0 0 M G E U R O P H A R M LAB CO LTD 
i ULCIMET 200 TAB 200MG, 400 TAB 400MG NATURAL HEALTH RESOURCES COMPANY 
i ULCOMET TAB 200MG, 400MG STAR MEDICAL SUPPLIES LTD 
69 ULSIKUR TAB 200MG, 400MG HANG LUNG TRADING (H.K.) CO 
~70ULTIDINE-200, 400 TAB FILM COATED VIDA LAB LTD 
~ 7 1 U N 1 M E T 400 CAP 400MG UNICORN LAB 
~72WEICQMET-200 , 400 TAB FILM COATED VIDA LAB LTD 
~73~ WETIDINE TAB 200MG (LIN CHEM) LAN WAY LTD 




Potential and Documented Interactions of Herbs with Warfarin 
> Danshen (丹參） 
> Devil's claw 
> Dong quai (當歸） 
> Papain (木瓜酵素） 
> Vitamin E (> 400 IU) 
> Coenzyme Qio 
> Ginseng (人參） 
> Green tea« (綠茶） 
> Angelica root (白芷屬根） > Gingko (銀杏） 
> Arnica flower (金車草花） > Horse chestnut (七葉樹） 
> Anise (茴香） > Licorice root (甘草根） 
> Asafoetida (阿魏樹脂） > Lovage root (拉維紀草） 
> Bog bean (睡菜） > Meadowsweet (繍線菊） 
> Borage seed oil (琉璃苣籽油） > Onion (洋蔥） 
> Bromelain (鳳梨酵素） > Parsley (皺葉歐芹，洋莞荽） 
> Capsicum (辣椒） > Passionflower herb (西番蓮） 
> Celery (芹菜） > Poplar (白楊） 
> Chamomile (洋甘菊） > Quassia (苦木） 
> Clove (丁香） > Red clover (紅苜蓿） 
> Fenugreek (葫蘆巴） > Rue (芸香） 
> Feverfew (艾菊,小白菊） > Sweet clover (香苜蓿） 
> Garlic (大蒜） > Turmeric (姜黃，沈金） 
> Ginger (薑） > Willow bark (柳樹皮） 
^Excessive amounts are necessary for this interaction to occur 
Reference: Heck: Am J Health Syst Pharm 2000; 57:1221-1230 
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W a r f a r i n - d r u g Interactions 
1. Vitamin K content of selected food 
Very High High Medium Low 
(>200 ^jg) (100-200 ^Jg) (50-100 ^ig) (<50 飓) 
Brussel sprouts Basil Apple, green Apple, red 
Chick pea Broccoli Asparagus Avocado 
Collard green Canola oil Cabbage Beans 
Coriander Chive Cauliflower Breads, grains 
Endive Coleslaw Mayonnaise Carrot 
Kale Cucumber (with peel) Nuts, pistachio Celery 
Lettuce, red leaf Green onion / scallion Squash, summer Cereal 
Liver Lettuce, butterhead Coffee 
Parsley Mustard greens Corn 
Spinach Soybean oil Cucumber (without 
Swiss chard P e e 0 
Tea, black Dairy products 
Tea, green Eggs 
Turnip green Fruits (varies) 
Watercress Lettuce, iceberg 







Reference: Pharmacotherapy A Pathophysiologic Approach 5th Edition, McGraw Hill 
2. Dietary supplements which contain vitamin K 
• Enercal Plus 
• Ensure / Ensure Plus / Ensure with Fiber 
• Glucerna / Glucerna SR 
• Isocal / Isocal H N 
• Isosource 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Data Collection Form 
96 
School of Pharmacy & Department of Medicine & Therapeutics, CUHK C o m p l i c a t i o n s 
Comparison of AC & UMC - Impact on clinical outcomes & healthcare costs H 
Patient No.: Patient Initial: 
Patient Profile 
Sex: M / F Study Group: A C / U M C 
Body Weight: kg Date of Birth: / /19 
Telephone Nos.: (Home) (Mobile) 
Indication(s) for warfarin: 
Target INR: Start day: / /200一 
Expected length of therapy: For months / Lifelong 
Tobacco consumption: Yes / No (If yes, cigarettes/d) 
Alcohol consumption: Regular / Occasional / No(If regular, cups/day) 
Clinical Diagnosis 
Medical Condition Year Remark 
Appendix B 
School of Pharmacy & Department of Medicine & Therapeutics, CUHK Other 
Comparison of AC & UMC 一 Impact on clinical outcomes & healthcare costs Medications 
Patient No.: Patient Initial: 
Other Medications (Including prescription drugs, OTC drugs and supplements) 
Medication Date Started Day Stopped PIIndex+ Category* Remark 
•Category includes +DI Index (Significance rating from Drug Interaction Facts) 
(1) prescription drugs, (1) Severity: major; Documentation: suspected o r � 
(2) OTC drugs (2) Severity: moderate; Documentation: suspected or > 
({) vitamins minerals, (3) Severity: minor; Documentation: suspected or > 
W) herbals (4) Severity: major/moderate; Documentation: possible 



























































































































































































































































































































































































































































































































































































































































































































































































































































School of Pharmacy & Department of Medicine & Therapeutics, CUHK Compl icat ions 
Comparison of AC & UMC - Impact on clinical outcomes & healthcare costs H 
Patient No.: Patient Initial: 
Antidote administration, Unscheduled clinic visit, A&E admission and Hospitalization 
Date~ Nature* Reason Warfarin- Bleeding/ Remarks 
related? TE? 

















"9 ‘ BG/TE 




















*Nature includes (1) Antidote Administration, (2) Unscheduled clinic visit, (3) A&E admission & (4) 
Hospitalization. 
今BG — bleeding; TE — Thromboembolism , n . 
®Classification of BG/TE: (1) minor, (2) serious, (3) life-threatening, (4)fatal (Ann Intern Med 1993, 
118: 511-520) 
Appendix B 
School of Pharmacy & Department of Medicine & Therapeutics, CUHK 
Comparison of AC & UMC - Impact on clinical outcomes & healthcare costs Hospitalization 
Patient No.: Patient Initial: 
Hospitalization Record (Ref. No.： ) 
Reason for admission 
• Thromboembolism: PE / D V T / C V A I others: 
• Bleeding: Site of bleeding: 
Date of admission: / /20 Date of discharge: / _ / 2 0 — — 
Length of stay: days 
Type of ward: Medical ICCUIICU / Other: 
Surgery done 
Date Details Date Details 
Laboratory and diagnostic test(s) done 
Date Details ^Jl Details 
Medication(s): 





1 0 4 
Patient Satisfaction Questionnaire 
20 
_ I . . .- _,••丨 ““」 . . - . - ‘ ' J .. ““““ . 
SHORT-FORM PATIENT SATISFACTION QUESTIONNAIRE (PSQ-18) 
These next questions are about how you feel about the medical care you receive. 
On the following pages are some things people say about medical care. Please read eacn one 
carefully, keeping in mind the medical care you are receiving now. (If you have not received 
care recently, think about what you would expect if you needed care today.) We are interested 
in your feelings, good and M d , about the medical care you have received. 
How strongly do you AGREE or DISAGREE with each of the following statements? 
(Circle One Number on Each Line) 
Strongly Strongly . 
Agree Agree Uncertain Disagree Disagree 
1. Doctors are good about explaining the 
reason for medical tests 1 2 3 4 5 
2. I think my doctor's office has 
everything needed to provide 
complete medical care 1 2 3 4 5 
3. The medical care 丨 have been 
receiving is just about perfect 1 2 3 4 5 
4. Sometimes doctors make me wonder 
if their diagnosis is correct 1 2 3 4 5 
5. I fee丨 confident that I can get the 
medical care I need without being set 
back financially 1 2 3 4 5 
6. When I go for medical care, they are 
careful to check everything when 
treating and examining me 1 2 3 4 5 
7. I have to pay for more of my medical 
care than I can afford 1 2 3 4 5 
8. I have easy access to the medical 
specialists I need 1 2 3 4 5 
Patient Satisfaction Questionnaire 
2 1 
How strongly do you AGREE or DISAGREE with fi^ of the following statements? 
(Circle One Number on Each Line) 
Strongly � Strongly 
Agree A g r e e Uncertain ... Disagree ^isagr^Q 
9. Where I get medical care, people 
have to wait too long for emergency 1 2 3 4 5 
treatment 
10. Doctors act too businesslike and 1 2 3 4 5 
impersonal toward me 
11. My doctors treat me in a very friendly 2 3 4 5 
and courteous manner 
12. Those who provide my medical care 
sometimes hurry too much when they 2 3 4 5 
treat me 
13. Doctors sometimes ignore what I tell 9 3 4 5 
them 1 ^ 
14.丨 have some doubts about the ability 2 3 4 5 
of the doctors who treat me 1 
15. Doctors usually spend plenty of time 2 3 4 5 
with me 
16. I find it hard to get an appointment for 2 3 4 5 
medical care right away 1 
17. I am dissatisfied with some things p 3 4 5 
about the medical care I receive 1 d 
18. I am able to get medical care 1 2 3 4 5 
whenever I need it 
• 
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